This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept
Pandemic response
COVID-19 is impacting communities around the world. PATH and our partners are responding.

Pneumonia

  1. PATH is on the front lines of an effort to defeat meningitis by 2030.
    Published: May 2020
    Type: Article
  2. Nipah virus has pandemic and bioterrorism potential. A vaccine candidate has entered a Phase 1 trial.
    Published: April 2020
    Type: Article
  3. Unknowns surround COVID-19, but hope lies in what we know about treating pneumonia.
    Published: March 2020
    Type: Article
  4. This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on worldwide. (This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.)
    Published: March 2020
    Type: Resource Page
  5. This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention. Sources of information for these trials are clinicaltrials.gov; who.int/ctrp; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries. Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. (This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.)
    Published: March 2020
    Type: Resource Page
  6. In less than two weeks a communicable diseases surveillance system was adapted to track COVID-19 digitally.
    Published: March 2020
    Type: Article
  7. PATH is part of a global task force working to eliminate meningitis as a public health threat by 2030
    Published: February 2020
    Type: Article
  8. With a recent approval from the World Health Organization, this high-quality, more affordable vaccine is poised to help more countries access protection against the top cause of deadly childhood pneumonia.
    Published: December 2019
    Type: Article
  9. This fact sheet provides an overview of pneumonia and other pneumococcal diseases, including disease burden and prevention and treatment measures. It also summarizes the pneumococcal conjugate vaccine (PCV) landscape, including the addition of Serum Institute of India, Pvt., Ltd.'s PCV (PNEUMOSIL®) to the suite of World Health Organization (WHO) prequalified PCVs. Also described are the Phase 3 clinical study results that constituted the pivotal data required for WHO prequalification.
    Published: December 2019
    Type: Resource Page
  10. Scaling up access to oxygen is a multifaceted challenge that cuts across health areas and requires technical, financial, and political solutions. The National Scale-Up of Medical Oxygen Implementation Plan is the first policy of its kind to coordinate oxygen stakeholders and provide long-term guidance for scaling oxygen access in Uganda.
    Published: November 2019
    Type: Resource Page
Load more